Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Gary Hudes;Michael Carducci;Piotr Tomczak;Janice Dutcher.
The New England Journal of Medicine (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Helmut Oettle;Stefan Post;Peter Neuhaus;Klaus Gellert.
JAMA (2007)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari.
Journal of Clinical Oncology (2012)
Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy
Hendrik Pels;Ingo G.H. Schmidt-Wolf;Axel Glasmacher;Holger Schulz.
Journal of Clinical Oncology (2003)
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani;Bertrand Coiffier;Myron S. Czuczman;Martin Dreyling.
Journal of Clinical Oncology (2010)
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
Kai Neben;Henk M. Lokhorst;Anna Jauch;Uta Bertsch.
Blood (2012)
RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
Verena I. Gaidzik;Lars Bullinger;Richard F. Schlenk;Andreas S. Zimmermann.
Journal of Clinical Oncology (2011)
Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients
Axel Glasmacher;Archibald Prentice;Marcus Gorschlüter;Steffen Engelhart.
Journal of Clinical Oncology (2003)
Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial.
Angela Märten;Dimitri Flieger;Sabine Renoth;Silvia Weineck.
Cancer Immunology, Immunotherapy (2002)
Non-viral and hybrid vectors in human gene therapy: an update
Gabriele D Schmidt-Wolf;Ingo G.H Schmidt-Wolf.
Trends in Molecular Medicine (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Bonn
University Hospital Heidelberg
Heidelberg University
Freie Universität Berlin
Erasmus University Rotterdam
University Hospital Bonn
University Hospital Heidelberg
University Hospital Bonn
University of Cologne
University of Ulm
Bahria University
Rensselaer Polytechnic Institute
Polish Academy of Sciences
University of Calgary
University of Cagliari
Spanish National Research Council
Cornell University
Centre national de la recherche scientifique, CNRS
Otsuka Pharmaceutical (Spain)
University of California, Los Angeles
Complutense University of Madrid
University of California, Los Angeles
University of Maryland, College Park
University of Essex
Ludwig-Maximilians-Universität München
Centers for Disease Control and Prevention